



Pegcetacoplan

Revised: August 15, 2023.

CASRN: 2019171-69-6

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of pegcetacoplan during breastfeeding. Since only a small dose is injected intravitreally into the eye, it is unlikely that a clinically relevant amount would reach the infant in breastmilk. With the systemic administration of pegcetacoplan, the manufacturer recommends that breastfeeding be discontinued during treatment and for 40 days after the last dose. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Paroxysmal Nocturnal Hemoglobinuria) [Eculizumab](#)

Substance Identification

Substance Name

Pegcetacoplan

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

CAS Registry Number

2019171-69-6

Drug Class

Breast Feeding

Lactation

Milk, Human

Complement Inactivating Agents